Genfit (GNFT) AI Stock Analysis

• Market Cap: €452.76M
• Dividend Yield: N/A
• Average Volume (3M): 245.75K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.48
• Revenue Growth: -45.41%
• EPS Growth: -273.69%
• Country: FR
• Employees: 180
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.20
• Shares Outstanding: 50,036,790
• 10 Day Avg. Volume: 239,968
• 30 Day Avg. Volume: 245,745
• PEG Ratio: -1.12
• Price to Book (P/B): 2.57
• Price to Sales (P/S): 2.65
• P/FCF Ratio: 12.50
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: €8.38
• Price Target Upside: -5.22% Downside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1
• EPS Forecast (FY): -0.23
• Revenue Forecast (FY): €59.34M

• Rating: 58 Neutral
• Price Target: €6.50 ▼(-26.47% Downside)
• Action: Reiterated Date: 02/04/26
• Date: Action: Reiterated 02/04/26

The score is driven primarily by improved 2024 financial performance and strong cash generation, supported by a bullish price trend. These positives are balanced by historically volatile revenue/cash flows and declining assets, while valuation is weaker due to a negative P/E and no dividend yield data.

Positive Factors

Return to profitability

Genfit's 2024 return to profitability, coupled with an exceptionally high gross margin, indicates the company can convert revenue to profit when sales stabilize. Durable operational improvements and stronger EBIT/EBITDA margins suggest operating leverage that can support continued R&D funding and program advancement over months.

Strong cash generation

Elevated free cash flow relative to earnings and strong operating cash conversion show Genfit is generating cash from operations rather than relying solely on financing. This improves the company's ability to fund clinical programs, meet milestone obligations and sustain operations through development timelines over the medium term.

Balanced capital structure

A moderate debt-to-equity ratio and a near 46% equity ratio indicate a balanced use of leverage and a meaningful equity cushion. This structural balance supports access to debt financing if needed while preserving capacity to absorb clinical or program setbacks without immediate solvency pressure.

Negative Factors

Volatile revenue trends

Historically volatile revenues and a large negative multi-year growth figure undermine predictability of top-line performance. For a biotech reliant on milestone/licensing timing and clinical progress, this volatility reduces visibility into sustainable cash inflows and complicates multi-quarter planning and investment decisions.

Declining total assets

A meaningful decline in total assets can reflect disposals, impairments or shrinking operational scale, weakening the company's resource base. Over a 2–6 month horizon this reduces collateral for lenders, limits balance-sheet flexibility and may constrain the scope or pace of clinical and commercial programs.

Low shareholder returns

A low ROE signals limited profitability relative to shareholder capital. For investors and potential partners this suggests capital is not being converted efficiently into returns, which can make raising equity or securing favorable partnership terms harder and pressure long-term funding options.

Genfit Business Overview & Revenue Model

Company Description

Genfit S.A., a biopharmaceutical company, discovers and develops drug candidates and diagnostic solutions for metabolic and liver-related diseases. The company's products include Elafibranor, which is in Phase 3 clinical trial to treat patients with primary biliary cholangitis. It also engages in the development of NIS4 technology for the diagnosis of nonalcoholic steatohepatitis (NASH) and fibrosis; GNS561, which is in Phase 1b/2 trial to treat patients with cholangiocarcinoma (CCA); and Nitazoxanide, which is in Phase 1 trial to treat acute-on-chronic liver failure. The company has a licensing agreement with Labcorp for the commercialization of NASHnext, a blood-based molecular diagnostic test; and with Genoscience Pharma to develop and commercialize the investigational treatment GNS561 for CCA. Genfit S.A. was incorporated in 1999 and is headquartered in Loos, France.

How the Company Makes Money

Genfit generates revenue through a combination of product development, licensing agreements, and collaborations with pharmaceutical companies. Key revenue streams include milestone payments and royalties from partnered drug candidates, particularly in the context of its lead asset, Elafibranor, which is in clinical development for NASH. Additionally, the company may receive funding from grants and research contracts aimed at advancing its scientific initiatives. Strategic partnerships with larger pharmaceutical firms enhance Genfit's financial stability and allow for shared resources in research, which can lead to significant financial returns upon the successful commercialization of its products.

Genfit Financial Statement Overview

Summary

2024 shows a meaningful turnaround with a return to profitability (net margin 2.25%), very strong gross margin (99.55%), and improved EBIT/EBITDA margins. Cash generation is strong versus earnings (FCF to net income 9.44; operating cash flow to net income 10.09). Offsetting this, revenue and operating cash flows have been historically volatile, and total assets have declined, creating sustainability risk despite a moderate debt-to-equity ratio (0.90) and decent equity ratio (45.73%).

Income Statement

Genfit experienced a significant recovery in 2024 with a substantial increase in revenue from 2023, resulting in a return to profitability with a net profit margin of 2.25%. The gross profit margin is robust at 99.55%, indicating effective cost management. EBIT and EBITDA margins have improved significantly, reflecting enhanced operational efficiency. However, the revenue growth has been volatile over the years, indicating a lack of stability in sales performance.

Balance Sheet

The company's financial structure shows a moderate debt-to-equity ratio of 0.90, indicating a balanced use of debt and equity. Return on Equity (ROE) is modest at 2.18%, suggesting limited profitability for shareholders. The equity ratio of 45.73% indicates a healthy balance sheet with adequate equity cushion. However, the substantial decrease in total assets over recent years might pose a risk to long-term asset sustainability.

Cash Flow

Genfit's cash flow position has improved, with a strong free cash flow growth from the previous year and a solid free cash flow to net income ratio of 9.44. The operating cash flow to net income ratio of 10.09 demonstrates effective cash generation from operations. However, the past volatility in operating cash flows might indicate future cash flow uncertainties.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	45.13M	67.00M	28.57M	20.20M	80.07M	765.00K
Gross Profit	42.00M	66.70M	28.22M	19.95M	79.91M	563.00K
EBITDA	-23.26M	8.35M	-22.24M	-23.60M	71.89M	-73.03M
Net Income	-38.76M	1.51M	-28.89M	-23.72M	67.26M	-101.22M
Balance Sheet
Total Assets	216.68M	151.42M	173.87M	215.54M	281.72M	198.61M
Cash, Cash Equivalents and Short-Term Investments	107.51M	81.79M	77.79M	140.55M	258.76M	171.03M
Total Debt	138.91M	62.13M	70.18M	75.28M	74.23M	185.69M
Total Liabilities	164.21M	82.20M	105.92M	121.01M	162.62M	214.78M
Stockholders Equity	52.47M	69.22M	67.95M	94.53M	119.10M	-16.16M
Cash Flow
Free Cash Flow	-4.47M	14.22M	-57.92M	-72.64M	99.38M	-97.27M
Operating Cash Flow	-3.18M	15.20M	-55.43M	-72.64M	99.92M	-96.37M
Investing Cash Flow	-3.57M	-1.04M	2.23M	-46.27M	-3.38M	-966.00K
Financing Cash Flow	52.75M	-10.57M	-5.10M	-3.79M	-8.92M	-8.26M

Genfit Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.84
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Negative
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:GNFT, the sentiment is Positive. The current price of 8.84 is above the 20-day moving average (MA) of 7.11, above the 50-day MA of 6.01, and above the 200-day MA of 4.25, indicating a bullish trend. The MACD of 0.86 indicates Negative momentum. The RSI at 82.32 is Negative, neither overbought nor oversold. The STOCH value of 93.15 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for FR:GNFT.

Genfit Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
GNFT	58 Neutral	€452.76M	-11.66	-51.06%	―	-45.41%	-273.69%
ABVX	53 Neutral	€8.65B	-37.92	―	―	―	18.52%
DBV	52 Neutral	€1.05B	-4.07	-241.12%	―	―	3.09%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
NANO	49 Neutral	€1.05B	―	―	―	―	―
OSE	49 Neutral	€95.33M	-2.78	-52.76%	―	-96.92%	-175.84%
IPH	47 Neutral	€139.65M	-2.70	-271.32%	―	-75.86%	-30.54%